- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01630759
Remote Monitoring of Diabetes in Pregnancy: a Feasibility Study (Tele-Mum)
Remote Monitoring of Diabetes in Pregnancy: a Feasibility Study for a Randomised Controlled Trial
When women with diabetes become pregnant it is particularly important to control blood sugar levels to prevent complications. Women are advised to test their blood glucose levels seven times a day and to attend antenatal and diabetes clinics every 1-2 weeks throughout the pregnancy. For those living in rural areas in the North and West of Ireland getting to a hospital specialising in the management of diabetes and pregnancy on such a regular basis can be a challenge.
Telemonitoring provides a possible solution to this problem by allowing patients to monitor their vital signs at home and transmit the information via telephone to their healthcare provider. If women could be safely monitored remotely for every other appointment it would mean that they would only need to visit the hospital once a month on a routine basis but with the option of attending the hospital if the remote telemonitoring indicated that this were necessary.
The aim of this study is to assess the feasibility and the acceptability of using remote telemonitoring facilities between antenatal women with gestational diabetes and the diabetes team and the possibility of replacing alternate diabetic review clinics with remote telemonitoring. In addition this study will explore the feasibility of running a full randomised control trial of this topic.
Women will be asked to monitor their blood sugar levels seven times a day which is part of usual care. However those in the remote telemonitoring group will be asked to measure their blood sugar using a meter that can transmit the results via a telephone line and to transmit them weekly. They will also be asked to measure their blood pressure and weight weekly and to download these results weekly for a health care professional to review. These results will be reviewed on a weekly basis by a health care professional who will contact the patient if necessary to discuss the results. Women will be followed-up from the date of diagnosis through to delivery.
Both staff and patients will be asked to give their views on the safety and acceptability of remote telemonitoring through questionnaires, focus groups or interviews. The management decisions made on reviewing the intervention group in clinic and reviewing remote telemonitoring results will also be recorded. In order for remote telemonitoring to be a viable replacement for clinic review it must allow health care professionals to make comparable management decisions. Clinical data will be collected in order to provide descriptive statistics for those who take part and to ensure that this information could be collected in any future Randomised Control Trial (RCT) looking at this topic.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Donegal
-
Letterkenny, Donegal, Ireland
- Letterkenny General Hospital
-
-
-
-
-
Londonderry, United Kingdom, BT47 6SB
- Altnagelvin Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant
- Gestational Diabetes or IGT following an oral glucose tolerance test performed at the 24-28 week screening appointment
- Able to use the telehealth equipment following training by staff from the company providing telehealth services
- Have sufficient communication skills [hearing, speech & language] to be fully involved.
- Willing to use one of the approved blood glucose meters for self monitoring of blood glucose, for the duration of the study.
Exclusion Criteria:
- Previously diagnosed Type 1 diabetes or Type 2 diabetes as evidenced by medical records.
- Other diagnosed medical problems or medical therapy such as steroid therapy that would influence blood glucose control and to be decided by the endocrinologist prior to recruitment. Such exclusions to be noted by the endocrinologist or diabetes nurse specialist.
- Previous gestational diabetes is not an exclusion criterion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Telemonitoring
The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week.
This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study.
Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
|
Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
|
|
ACTIVE_COMPARATOR: Control group
Control group will consist of usual care and review at clinic.
|
The control group will receive usual diabetes/antinatal care.
The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient satisfaction
Time Frame: At 36-39 weeks gestation
|
The previously validated 'Telemedicine satisfaction and usefulness questionnaire' will be used to assess patient satisfaction with the telemonitoring service. Qualitative interviews exploring the patient experience of telemonitoring will also be carried out and then analysed using the framework approach. An adapted version of this questionnaire looking specifically at the use of a blood glucose meter will be given to the control group. |
At 36-39 weeks gestation
|
|
Health care staff satisfaction
Time Frame: At completion of the study estimated to be January 2013
|
The professionals involved in caring for the women using remote telemonitoring technology in antenatal or diabetes clinics will be invited to take part in a focus group at each site.
If it is not possible to arrange a time and place suitable for staff in order to hold a focus group it may be necessary to hold one to one structured interviews with staff.
The questions used in the focus group will aim to assess the acceptability of telemonitoring to health care staff who use it.
|
At completion of the study estimated to be January 2013
|
|
Management decision comparison
Time Frame: At weekly clinic or telemonitoring review from time recruited into study to delivery, estimated at an average of twelve weeks.
|
Weighted kappa will be used to meaure the level of agreement in between clinic and telemonitoring review management decisions (in excess of the amount of agreement that we would expected by chance).
This will allow the determination of inter-rater, intra-rater and inter-institutional agreement between clinic and telemonitoring review management decisions.
|
At weekly clinic or telemonitoring review from time recruited into study to delivery, estimated at an average of twelve weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c
Time Frame: Monthly for duration of participation in study, estimated at 2-3 months
|
HbA1c mmol/l and IFCC units
|
Monthly for duration of participation in study, estimated at 2-3 months
|
|
Mean fasting blood glucose
Time Frame: Weekly for duration of participation in study, estimated at 12 weeks
|
mmol/l plasma glucose
|
Weekly for duration of participation in study, estimated at 12 weeks
|
|
Blood pressure
Time Frame: Weekly for duration of participation in study, estimated at 12 weeks
|
mmHg
|
Weekly for duration of participation in study, estimated at 12 weeks
|
|
Gestational age at delivery
Time Frame: At delivery
|
Gestational age in weeks at delivery
|
At delivery
|
|
Type of delivery
Time Frame: At delivery
|
Vaginal or Caesarean section
|
At delivery
|
|
Pre-eclampsia
Time Frame: At delivery
|
Presence or absence of any pre-eclampsia
|
At delivery
|
|
Documented problems with pregnancy
Time Frame: At delivery
|
Presence of any documented problems during pregnancy
|
At delivery
|
|
Weight of baby
Time Frame: At birth
|
Weight in kg
|
At birth
|
|
Apgar score
Time Frame: At birth
|
Apgar score at one and five minutes (out of 10)
|
At birth
|
|
Admission to neonatal unit
Time Frame: At one day after birth
|
Whether the baby needed admission to the neonatal unit
|
At one day after birth
|
|
Respiratory distress
Time Frame: At one day after birth
|
Presence of any episodes of documented Respiratory distress in first 24 hours of life
|
At one day after birth
|
|
Jaundice
Time Frame: At one day after birth
|
Presence of any jaundice in first 24 hours of life
|
At one day after birth
|
|
Neonatal hypoglycaemia
Time Frame: At one day after birth
|
Presence of any documented episodes of neonatal hypoglycaemia in first 24 hours of life
|
At one day after birth
|
|
Shoulder dystocia
Time Frame: At birth
|
Presence of any shoulder dystocia
|
At birth
|
|
Malformations
Time Frame: At delivery
|
Any malformations at delivery
|
At delivery
|
|
Post-prandial blood glucose
Time Frame: Weekly for duration of participation in study, estimated at 12 weeks
|
mmol/l plasma glcuose
|
Weekly for duration of participation in study, estimated at 12 weeks
|
|
Length of baby
Time Frame: At birth
|
centimeters
|
At birth
|
|
Macrosomia
Time Frame: At birth
|
Presence or absence of macrosomia
|
At birth
|
|
Head circumference
Time Frame: At birth
|
centimeters
|
At birth
|
|
Average number of monitoring episodes per day
Time Frame: At delivery
|
Average number of monitoring episodes per day
|
At delivery
|
|
Number of downloads missed
Time Frame: At delivery
|
Number of downloads missed by those in the telemonitoring group
|
At delivery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vivien E Coates, PhD, University of Ulster
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11/0016
- 11/NI/0023 (OTHER: ORECNI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
Royal College of Surgeons, IrelandHealth Research Board - Trials Methodology Research NetworkCompletedPre-Gestational DiabetesIreland
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
University of Tennessee Graduate School of MedicineRecruitingInsulin Resistance | Pregnancy Complications | Pregnancy | Preeclampsia | Gestational Diabetes | Gestational Diabetes Mellitus in Pregnancy | Placental Dysfunction | Gestational Diabetes Mellitus (GDM) | Preeclampsia (PE) | Cardiometabolic Diseases | Gestational Complications | Preeclampsia (PE) RiskUnited States
-
Lahore University of Biological and Applied SciencesNot yet recruitingPregnancy Complications | Gestational Diabetes Mellitus (GDM) | Diabetes During Pregnancy | Pregnancy in Diabetes | Gestational | Diabetes ComplicationPakistan
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
Clinical Trials on Telemonitoring
-
Aalborg University HospitalAalborg University; Steno Diabetes Center NordjyllandActive, not recruiting
-
Chang Hee, LeePurdue University; LG Electronics Inc.CompletedHypertensionKorea, Republic of
-
ResMedCompleted
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Societat Catalana de Pneumologia...RecruitingNon Invasive VentilationSpain
-
Istituto Auxologico ItalianoRecruiting
-
humanITcareUniversity of Barcelona; Hospital Universitario de Torrevieja; European Innovation...CompletedHeart FailureSpain, Romania
-
Research and Practical Clinical Center for Diagnostics...Sechenov UniversityEnrolling by invitationInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisRussian Federation
-
Hospital Universitari de BellvitgeInstitut d'Investigació Biomèdica de BellvitgeCompleted
-
Turku University HospitalUniversity of TurkuTerminated
-
International Society for Vascular HealthUnknown